NewslettersFall 2021


Study Titles in IRBNet Should Include Study Acronym (STISISA)

Moving forward, all new studies with an acronym in their study title should plan on including said acronym in the study title as entered in the IRBNet system. If you have an existing study with an acronym that is not currently included in the title in IRBNet, please flag your next package for a title update. You can update the study title on the ‘Project Overview’ page in IRBNet. Click the yellow ‘Edit’ link at the top of the page to revise the study title.


The reason for this request is so that our data commitments coordinator can easily locate your study in the data commitments system and in the IRBNet (without you having to memorize your project number). If your study did not come up with a clever acronym that required awkward wording of your study objectives, first, shame on you; the world needs laughter. Second, no need to come up with an acronym just for this purpose. We’ll make do.

New and Updated Guidance on Reliance Agreements

We’ve added a new flow chart to help guide you through establishing IRB reliance when KPNW is going to act as the IRB of record. The flow chart provides color-coded, step by step guidance in an easy to navigate format. Find the new flow chart, and the existing one for when KPNW relies on an external IRB, on the Reliance page of our website, under the ‘What to do: IRB Review’ section.  

Policy Updates

No policy updates to report.

IRB Tips and New Information

Announcements – Customer Service Survey

The Research Compliance team is releasing their annual customer service survey shortly. This survey will also include questions about the recent Research Compliance Quiet Week so we can gauge how it went. Please take a moment to answer the survey when you receive it.


If you plan to keep identifiable data and/or specimens for future research in the KPNW Research Bank (or anywhere for that matter), be sure to include adequate language in the consent for future research. See our consent template for boilerplate language.

Mark Mac’s Media Corner

If you’re a regular reader of Mark Mac’s Media Corner, you’re no doubt familiar with the story of Henrietta Lacks. The family of Henrietta Lacks has just filed suit against Fischer Scientific, one of many companies who propagate HeLa cells obtained from Johns Hopkins University and sell commercialized products made using them. We had a riveting discussion at last month’s IRB meeting about what would constitute justice being served in this instance, the ramifications for the biomedical industry, and the legal and ethical merits of the suit. We had a wide range of opinions expressed and it was clear that this is a complicated situation with no real clear answers as to what would constitute justice and whether the legal system is the appropriate venue for these considerations.

This recent NPR story discusses the family’s lawsuit: